Category: <span></span>
Since the beginning of the year, tobacco giant Altria saw its stock price dive. Investors may wonder if the dividend is safe.
Published:
The March 31 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks decreased.
Published:
Gun background checks soared in every state last month as people loaded up with firearms at an unprecedented rate. No populous state posted a bigger increase in these checks than Texas.
Published:
Can Aurora Cannabis do anything to avoid the same fate as its peers that are circling the drain? Can anything the company does return it to its former glory?
Published:
It’s no secret that the cannabis industry has been smoked so far in 2020. Out of this group, Organigram seems to have fared the best. What comes next?
Published:
Constellation Brands reported better than expected fiscal fourth-quarter financial results before the markets opened on Friday.
Published:
The U.S. Federal Trade Commission has filed a lawsuit alleging that Altria Group's $12.8 billion investment in e-cigarette maker Juul violated various U.S. antitrust laws.
Published:
Canadian pot grower Tilray has released 11 million shares of common stock that had been subject to a lockup period following the company's merger with its largest holder last September.
Published:
Investors are scrambling to find yield. Could Altria have just the dividend yield they are looking for? Cigarettes have been considered recession-proof, but this time things may be somewhat different.
Published:
Something is moving Tilray stock far higher than other pot stocks. What can account for a 67% one-day jump in the cannabis company's share price?
Published:
Stocks like Coca-Cola and PepsiCo were supposed to be about as defensive as they come. Two different analyst reports now suggest that their COVID-19 pandemic damage has been enough.
Published:
After brutal sell-offs during the past year, some of the cannabis stocks have bounced back, a relief for many investors. Is Aphria set to be a winner?
Published:
CannTrust has been one of the most beat-up marijuana stocks over the past year, but not without reason. Will the cannabis grower finally get its act together, or is this just a race to zero?
Published:
Independent research firm Argus raised its rating on Procter & Gamble to Buy from Hold. Its $122 target price represented almost 20% upside from the prior close.
Published:
With its massive exposure to China and global footprint, Nike was definitely hurt by the coronavirus, but earnings demonstrated why this company is strong.
Published: